CERO vs. PBM, NIVF, PRE, FHLT, AXDX, MEIP, OCX, DMTK, RNXT, and BIVI
Should you be buying CERo Therapeutics stock or one of its competitors? The main competitors of CERo Therapeutics include Psyence Biomedical (PBM), NewGenIvf Group (NIVF), Prenetics Global (PRE), Future Health ESG (FHLT), Accelerate Diagnostics (AXDX), MEI Pharma (MEIP), OncoCyte (OCX), DermTech (DMTK), RenovoRx (RNXT), and BioVie (BIVI). These companies are all part of the "medical" sector.
Psyence Biomedical (NASDAQ:PBM) and CERo Therapeutics (NASDAQ:CERO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and community ranking.
Psyence Biomedical has a beta of -0.11, meaning that its share price is 111% less volatile than the S&P 500. Comparatively, CERo Therapeutics has a beta of -0.08, meaning that its share price is 108% less volatile than the S&P 500.
Psyence Biomedical and CERo Therapeutics both received 0 outperform votes by MarketBeat users.
In the previous week, CERo Therapeutics had 1 more articles in the media than Psyence Biomedical. MarketBeat recorded 1 mentions for CERo Therapeutics and 0 mentions for Psyence Biomedical. CERo Therapeutics' average media sentiment score of 0.00 equaled Psyence Biomedical'saverage media sentiment score.
77.4% of Psyence Biomedical shares are owned by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are owned by institutional investors. 3.6% of Psyence Biomedical shares are owned by insiders. Comparatively, 15.8% of CERo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
CERo Therapeutics beats Psyence Biomedical on 3 of the 4 factors compared between the two stocks.
Get CERo Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CERO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CERO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CERo Therapeutics Competitors List
Related Companies and Tools
